{"groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib (BTZ) 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"FG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"FG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Placebo administered once IV on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"FG002","title":"Placebo Comparator: Placebo + Dexamethasone + Bortezomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Investigator Decison"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"72"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"72"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"66"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers are defined as participants who died or had disease progression or completed treatment or did not complete treatment and were followed for survival data."}